Use of anti-CD19 antibodies to treat autoimmune diseases
Patent Information
- Application Number
- JP2023526226
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-04-22
- Filing Date
- 2021-10-29
- Publication Date
- 2024-11-07
- Estimated Expiration
- 2041-10-29
Smart Images

Figure 00000049_0000 
Figure 00000049_0001 
Figure 00000049_0002
Abstract
Claims
1. For use in a method for treating neuromyelitis optica spectrum disorder (NMOSD), a heavy chain variable region (VH) complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO:5; a VH CDR2 comprising the amino acid sequence of SEQ ID NO:6; a VH CDR3 comprising the amino acid sequence of SEQ ID NO:7; a light chain variable region (VL) complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO:8; A VL CDR2 comprising the amino acid sequence of SEQ ID NO:9; and VL CDR3 comprising the amino acid sequence of SEQ ID NO:10 A pharmaceutical comprising an anti-CD19 antibody comprising the method comprising administering the anti-CD19 antibody to a subject who has previously been treated with an anti-CD20 antibody. The said medicine.
2. The pharmaceutical described in claim 1, wherein the anti-CD19 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:
2.
3. The pharmaceutical described in claim 1 or 2, wherein the anti-CD19 antibody is inebilizumab.
4. The pharmaceutical agent described in any one of claims 1 to 3, wherein the subject experiences an NMOSD attack while being treated with the anti-CD20 antibody or within 6 months of the last administration of the anti-CD20 antibody.
5. The pharmaceutical composition of claim 4, wherein the NMOSD seizures include one or more of optic neuritis, myelitis, or brainstem seizures.
6. The pharmaceutical agent of any one of claims 1 to 5, wherein the method comprises administering the anti-CD19 antibody intravenously to a subject at a dose of 300 mg every six months.
7. 6. The medicament of any one of claims 1 to 5, wherein the method comprises intravenously administering the anti-CD19 antibody to a subject at a first initial dose of 300 mg, at a second initial dose of 300 mg two weeks after the first initial dose, and at subsequent doses of 300 mg every six months after the first initial dose.
8. The pharmaceutical composition of claim 7, wherein the method comprises simultaneously administering a corticosteroid to the subject together with the first initial dose.
9. The pharmaceutical composition of claim 1, wherein the anti-CD20 antibody is selected from the group consisting of rituximab, ABP-300, B-001, BAT-4306F, BAT-4406F, BCD-132, BVX-20, CYT-202, epcolitamab, GB-261, GD-CO1620, glofitamab, HS-006, IGM-2323, IMM-0306, MIL-62, mosunetuzumab, MRG-001, obinutuzumab, ocrelizumab, odronextamab, ofatumumab, pramotamab, SM-09, TRS-005, ublituximab, and YBL-031.
10. The pharmaceutical composition of claim 9 , wherein the anti-CD20 antibody is rituximab.
11. The pharmaceutical composition according to any one of claims 1 to 10, wherein the subject is astrocyte water channel aquaporin-4 (AQP4)-immunoglobulin (Ig)G serum positive.
12. The method according to claim 1, further comprising, prior to said administering: confirming that the subject has previously been treated with the anti-CD20 antibody; The object is (i) experienced at least one NMOSD attack while being treated with the anti-CD20 antibody; or (ii) had at least one NMOSD attack within 6 months of the last dose of the anti-CD20 antibody; determining selecting said subject for administration of said anti-CD19 antibody as a result of the determination of (i) or (ii). The pharmaceutical composition according to any one of claims 1 to 11, further comprising:
13. For use in a method for treating neuromyelitis optica spectrum disorder (NMOSD), a heavy chain variable region (VH) complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO:5; a VH CDR2 comprising the amino acid sequence of SEQ ID NO:6; a VH CDR3 comprising the amino acid sequence of SEQ ID NO:7; a light chain variable region (VL) complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO:8; A VL CDR2 comprising the amino acid sequence of SEQ ID NO:9; and VL CDR3 comprising the amino acid sequence of SEQ ID NO:10 A pharmaceutical comprising an anti-CD19 antibody comprising the method comprising administering the anti-CD19 antibody to a subject who has previously been treated with an anti-CD20 antibody and who is astrocyte water channel aquaporin-4 (AQP4)-immunoglobulin (Ig)G seropositive. The said medicine.
14. The pharmaceutical described in claim 13, wherein the anti-CD19 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:
2.
15. The pharmaceutical described in claim 13 or 14, wherein the anti-CD19 antibody is inebilizumab.
16. The pharmaceutical agent described in any one of claims 13 to 15, wherein the subject experiences an NMOSD attack while being treated with the anti-CD20 antibody or within 6 months of the last administration of the anti-CD20 antibody.
17. The pharmaceutical agent of any one of claims 13 to 16, wherein the method comprises intravenously administering the anti-CD19 antibody to a subject at a dose of 300 mg every six months.
18. The pharmaceutical agent of any one of claims 13 to 16, wherein the method comprises intravenously administering the anti-CD19 antibody to a subject at a first initial dose of 300 mg, at a second initial dose of 300 mg two weeks after the first initial dose, and at subsequent doses of 300 mg every six months after the first initial dose.
19. The pharmaceutical composition of claim 18, wherein the method comprises simultaneously administering a corticosteroid to the subject together with the first initial dose.
20. The pharmaceutical composition of any one of claims 13 to 19, wherein the anti-CD20 antibody is selected from the group consisting of rituximab, ABP-300, B-001, BAT-4306F, BAT-4406F, BCD-132, BVX-20, CYT-202, epcolitamab, GB-261, GD-CO1620, glofitamab, HS-006, IGM-2323, IMM-0306, MIL-62, mosunetuzumab, MRG-001, obinutuzumab, ocrelizumab, odronextamab, ofatumumab, pramotamab, SM-09, TRS-005, ublituximab, and YBL-031.
21. The pharmaceutical described in claim 20, wherein the anti-CD20 antibody is rituximab.
22. The pharmaceutical agent described in any one of claims 13 to 21, wherein the anti-CD19 antibody depletes peripheral blood CD20 - plasmablasts and plasma cells within 8 days after the administration.
23. The method according to claim 22, further comprising, prior to said administering: confirming that the subject has previously been treated with the anti-CD20 antibody; The object is (i) experienced at least one NMOSD attack while being treated with the anti-CD20 antibody; or (ii) had at least one NMOSD attack within 6 months of the last dose of the anti-CD20 antibody; determining selecting said subject for administration of said anti-CD19 antibody as a result of the determination of (i) or (ii). The pharmaceutical composition according to any one of claims 13 to 22, further comprising:
24. The treatment comprising: reducing deterioration of the Kurtzke Expanded Disability Status Scale (EDSS) in said subject; A reduction in the number of active magnetic resonance imaging (MRI) lesions; reducing the deterioration of the subject's modified Rankin score; A reduction in the frequency of hospitalization of said subject associated with NMOSD; A reduction in NMOSD-related pain in said subject; and / or Reducing the risk of NMOSD-related seizures in said subject The pharmaceutical composition according to any one of claims 13 to 23, which provides
25. For use in a method for reducing active MRI lesions in a subject diagnosed with NMOSD, a heavy chain variable region (VH) complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO:5; a VH CDR2 comprising the amino acid sequence of SEQ ID NO:6; a VH CDR3 comprising the amino acid sequence of SEQ ID NO:7; a light chain variable region (VL) complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO:8; A VL CDR2 comprising the amino acid sequence of SEQ ID NO:9; and VL CDR3 comprising the amino acid sequence of SEQ ID NO:10 A pharmaceutical comprising an anti-CD19 antibody comprising the method comprising administering the anti-CD19 antibody to a subject who has previously been treated with an anti-CD20 antibody. The said medicine.
26. The pharmaceutical composition of claim 25, wherein the subject has experienced an NMOSD attack within 6 months of the last administration of the anti-CD20 antibody.
27. For use in a method for reducing NMOSD-related disorders in a subject diagnosed with NMOSD, a heavy chain variable region (VH) complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO:5; a VH CDR2 comprising the amino acid sequence of SEQ ID NO:6; a VH CDR3 comprising the amino acid sequence of SEQ ID NO:7; a light chain variable region (VL) complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO:8; A VL CDR2 comprising the amino acid sequence of SEQ ID NO:9; and VL CDR3 comprising the amino acid sequence of SEQ ID NO:10 A pharmaceutical comprising an anti-CD19 antibody comprising the method comprising administering the anti-CD19 antibody to a subject who has previously been treated with an anti-CD20 antibody. The said medicine.
28. For use in a method for reducing NMOSD-associated seizures in a subject. a heavy chain variable region (VH) complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO:5; a VH CDR2 comprising the amino acid sequence of SEQ ID NO:6; a VH CDR3 comprising the amino acid sequence of SEQ ID NO:7; a light chain variable region (VL) complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO:8; A VL CDR2 comprising the amino acid sequence of SEQ ID NO:9; and VL CDR3 comprising the amino acid sequence of SEQ ID NO:10 A pharmaceutical comprising an anti-CD19 antibody comprising the method comprising administering the anti-CD19 antibody to a subject who has previously been treated with an anti-CD20 antibody. The said medicine.
29. For use in a method for treating NMOSD, a heavy chain variable region (VH) complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO:5; a VH CDR2 comprising the amino acid sequence of SEQ ID NO:6; a VH CDR3 comprising the amino acid sequence of SEQ ID NO:7; a light chain variable region (VL) complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO:8; A VL CDR2 comprising the amino acid sequence of SEQ ID NO:9; and VL CDR3 comprising the amino acid sequence of SEQ ID NO:10 A pharmaceutical comprising an anti-CD19 antibody comprising the method comprising intravenously administering the anti-CD19 antibody to a subject who has previously been treated with an anti-CD20 antibody at a first initial dose of 300 mg, at a second initial dose of 300 mg two weeks after the first initial dose, and at subsequent doses of 300 mg every six months after the first initial dose. The said medicine.
30. A pharmaceutical comprising an anti-CD19 antibody comprising a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:1 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:2 for use in a method for treating neuromyelitis optica spectrum disorder (NMOSD), comprising: the method comprising administering the anti-CD19 antibody to a subject who has previously been treated with an anti-CD20 antibody. The said medicine.
31. A pharmaceutical comprising an anti-CD19 antibody for use in a method for treating neuromyelitis optica spectrum disorder (NMOSD), comprising: the anti-CD19 antibody is inebilizumab, and the method comprising administering the anti-CD19 antibody to a subject who has previously been treated with an anti-CD20 antibody. The said medicine.
32. A pharmaceutical comprising an anti-CD19 antibody comprising a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:1 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:2 for use in a method for treating neuromyelitis optica spectrum disorder (NMOSD), comprising: the method comprising administering the anti-CD19 antibody to a subject who has previously been treated with an anti-CD20 antibody and who is astrocyte water channel aquaporin-4 (AQP4)-immunoglobulin (Ig)G seropositive. The said medicine.
33. A pharmaceutical comprising an anti-CD19 antibody for use in a method for treating neuromyelitis optica spectrum disorder (NMOSD), comprising: the anti-CD19 antibody is inebilizumab, and the method comprising administering the anti-CD19 antibody to a subject who has previously been treated with an anti-CD20 antibody and who is astrocyte water channel aquaporin-4 (AQP4)-immunoglobulin (Ig)G seropositive. The said medicine.
